Tackling Existential Crisis

Summary In this episode of the Med City Pivot Podcast, host Arundhati Parmar speaks with Lars Petersen about one of the most remarkable corporate transformations in modern business history. Facing a catastrophic collapse of its core film business in the mid-2000s due to the rise of digital photography, Fujifilm executed a bold and strategic pivot into healthcare and life sciences. The company diversified aggressively, leveraging its deep expertise in materials science, imaging, and innovation to build a thriving biotechnology and medical technology ecosystem. Today, Fujifilm operates as a global Contract Development and Manufacturing Organization (CDMO), partnering with leading pharmaceutical companies and startups alike. The conversation explores how strategic investment, diversification, long-term thinking, and innovation—including AI—enabled Fujifilm not just to survive, but to lead in a completely new industry. Links & Resources Connect with Arundhati Parmar [email protected]  https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Keywords Fujifilm Pivot Healthcare CDMO Biotechnology Biologics digital transformation business strategy Innovation AI in healthcare Pharma Manufacturing monoclonal antibodies gene therapy cell therapy Diversification corporate strategy MedTech Episode Highlights  00:00–00:23 – Introduction to the concept of "pivot" and Fujifilm's survival story 00:00–00:47 – The collapse of the film industry and existential crisis 00:00–01:15 – Fujifilm's transformation into a healthcare company 00:02:39–00:03:28 – 2006: the pivotal year and 60% revenue loss 00:03:28–00:03:45 – Strategic decision to diversify long-term 00:04:22–00:05:08 – Why Fujifilm succeeded while competitors failed 00:05:35–00:06:26 – Key investments and acquisitions (including Biogen assets) 00:06:52–00:07:30 – Why healthcare is a stable, long-term growth industry 00:07:53–00:08:29 – Expansion into medical devices and imaging technologies 00:09:42–00:10:34 – Core therapeutic focus: biologics, gene therapy, cell therapy 00:10:49–00:11:22 – Serving both startups and global pharma giants 00:12:39–00:13:40 – Competitive positioning vs. Samsung Biologics & Lonza 00:15:08–00:15:44 – "Partners for life" philosophy and long-term trust 00:17:52–00:18:49 – AI integration across manufacturing ecosystems 00:18:54–00:19:42 – Final takeaway: building shared ecosystems for the future of medicine